Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) shares in Millions, $ in Millions		Total	Total CVS Health Shareholders’ Equity	Common Shares	Treasury Stock		Common Stock and Capital Surplus		Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Noncontrolling Interests
Shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2020				1,733
Treasury shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2020	[1]				(423)
Balance at beginning of period at Dec. 31, 2020		$ 69,701	$ 69,389		$ (28,178)	[1]	$ 46,513	[2]	$ 49,640	$ 1,414	$ 312
Shareholders' Equity [Roll Forward]
Net income		2,224	2,223						2,223		1
Other comprehensive loss		(392)	(392)							(392)
Stock option activity, stock awards and other (in shares)				2
Stock option activity, stock awards and other		214	214				214	[2]
ESPP issuances, net of purchase of treasury shares (in shares)	[1]				1
ESPP issuances, net of purchase of treasury shares		76	76		$ 76	[1]
Common stock dividends		(660)	(660)						(660)
Other increases (decreases) in noncontrolling interests		1									1
Shares outstanding, balance at end of period (in shares) at Mar. 31, 2021				1,735
Treasury shares outstanding, balance at end of period (in shares) at Mar. 31, 2021	[1]				(422)
Balance at end of period at Mar. 31, 2021		71,164	70,850		$ (28,102)	[1]	46,727	[2]	51,203	1,022	314
Shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2020				1,733
Treasury shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2020	[1]				(423)
Balance at beginning of period at Dec. 31, 2020		69,701	69,389		$ (28,178)	[1]	46,513	[2]	49,640	1,414	312
Shareholders' Equity [Roll Forward]
Net income		5,015
Other comprehensive loss		(244)
Shares outstanding, balance at end of period (in shares) at Jun. 30, 2021				1,742
Treasury shares outstanding, balance at end of period (in shares) at Jun. 30, 2021	[1]				(424)
Balance at end of period at Jun. 30, 2021		73,565	73,244		$ (28,252)	[1]	46,995	[2]	53,331	1,170	321
Shares outstanding, balance at beginning of period (in shares) at Mar. 31, 2021				1,735
Treasury shares outstanding, balance at beginning of period (in shares) at Mar. 31, 2021	[1]				(422)
Balance at beginning of period at Mar. 31, 2021		71,164	70,850		$ (28,102)	[1]	46,727	[2]	51,203	1,022	314
Shareholders' Equity [Roll Forward]
Net income		2,791	2,783						2,783		8
Other comprehensive loss		148	148							148
Stock option activity, stock awards and other (in shares)				7
Stock option activity, stock awards and other		268	268				268	[2]
Purchases of treasury shares, net of ESPP issuances (in shares)	[1]				(2)
Purchase of treasury shares, net of ESPP issuances		(150)	(150)		$ (150)	[1]
Common stock dividends		(655)	(655)						(655)
Other increases (decreases) in noncontrolling interests		(1)									(1)
Shares outstanding, balance at end of period (in shares) at Jun. 30, 2021				1,742
Treasury shares outstanding, balance at end of period (in shares) at Jun. 30, 2021	[1]				(424)
Balance at end of period at Jun. 30, 2021		73,565	73,244		$ (28,252)	[1]	46,995	[2]	53,331	1,170	321
Shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2021				1,744
Treasury shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2021	[3]				(422)
Balance at beginning of period at Dec. 31, 2021		75,381	75,075		$ (28,173)	[3]	47,377	[4]	54,906	965	306
Shareholders' Equity [Roll Forward]
Net income		2,313	2,312						2,312		1
Other comprehensive loss		(1,155)	(1,155)							(1,155)
Stock option activity, stock awards and other (in shares)				3
Stock option activity, stock awards and other		300	300				300	[4]
Purchases of treasury shares, net of ESPP issuances (in shares)	[3]				(19)
Purchase of treasury shares, net of ESPP issuances		(1,972)	(1,972)		$ (1,972)	[3]
Common stock dividends		(730)	(730)						(730)
Other increases (decreases) in noncontrolling interests		3									3
Shares outstanding, balance at end of period (in shares) at Mar. 31, 2022				1,747
Treasury shares outstanding, balance at end of period (in shares) at Mar. 31, 2022	[3]				(441)
Balance at end of period at Mar. 31, 2022		74,140	73,830		$ (30,145)	[3]	47,677	[4]	56,488	(190)	310
Shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2021				1,744
Treasury shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2021	[3]				(422)
Balance at beginning of period at Dec. 31, 2021		75,381	75,075		$ (28,173)	[3]	47,377	[4]	54,906	965	306
Shareholders' Equity [Roll Forward]
Net income		5,274
Other comprehensive loss		(1,953)
Shares outstanding, balance at end of period (in shares) at Jun. 30, 2022				1,755
Treasury shares outstanding, balance at end of period (in shares) at Jun. 30, 2022	[3]				(443)
Balance at end of period at Jun. 30, 2022		75,506	75,184		$ (30,412)	[3]	47,874	[4]	58,710	(988)	322
Shares outstanding, balance at beginning of period (in shares) at Mar. 31, 2022				1,747
Treasury shares outstanding, balance at beginning of period (in shares) at Mar. 31, 2022	[3]				(441)
Balance at beginning of period at Mar. 31, 2022		74,140	73,830		$ (30,145)	[3]	47,677	[4]	56,488	(190)	310
Shareholders' Equity [Roll Forward]
Net income		2,961	2,951						2,951		10
Other comprehensive loss		(798)	(798)							(798)
Stock option activity, stock awards and other (in shares)				8
Stock option activity, stock awards and other		197	197				197	[4]
Purchases of treasury shares, net of ESPP issuances (in shares)	[3]				(2)
Purchase of treasury shares, net of ESPP issuances		(267)	(267)		$ (267)	[3]
Common stock dividends		(729)	(729)						(729)
Other increases (decreases) in noncontrolling interests		2									2
Shares outstanding, balance at end of period (in shares) at Jun. 30, 2022				1,755
Treasury shares outstanding, balance at end of period (in shares) at Jun. 30, 2022	[3]				(443)
Balance at end of period at Jun. 30, 2022		$ 75,506	$ 75,184		$ (30,412)	[3]	$ 47,874	[4]	$ 58,710	$ (988)	$ 322

[1] Treasury shares include 1 million shares held in trust and treasury stock includes $29 million related to shares held in trust as of June 30, 2021, March 31, 2021 and December 31, 2020.

[2] Common stock and capital surplus includes the par value of common stock of $17 million as of June 30, 2021, March 31, 2021 and December 31, 2020.

[3] Treasury shares include 1 million shares held in trust and treasury stock includes $29 million related to shares held in trust as of June 30, 2022, March 31, 2022 and December 31, 2021.

[4] Common stock and capital surplus includes the par value of common stock of $18 million as of June 30, 2022 and $17 million as of March 31, 2022 and December 31, 2021.